EA201491656A1 - Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения - Google Patents

Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения

Info

Publication number
EA201491656A1
EA201491656A1 EA201491656A EA201491656A EA201491656A1 EA 201491656 A1 EA201491656 A1 EA 201491656A1 EA 201491656 A EA201491656 A EA 201491656A EA 201491656 A EA201491656 A EA 201491656A EA 201491656 A1 EA201491656 A1 EA 201491656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding molecules
viruses
influenza
neutralize
applications
Prior art date
Application number
EA201491656A
Other languages
English (en)
Other versions
EA028433B1 (ru
Inventor
Теодорус Хендрикус Якобус Квакс
Роналд Вогелс
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA201491656A1 publication Critical patent/EA201491656A1/ru
Publication of EA028433B1 publication Critical patent/EA028433B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к связывающим молекулам, таким как моноклональные антитела человека, которые связываются с гемагглютинином вирусов гриппа В, и обладают широкой нейтрализующей активностью в отношении таких вирусов гриппа. Связывающие молекулы, которые не связываются с гемагглютинином вирусов гриппа А. Настоящее изобретение дополнительно предлагает молекулы нуклеиновой кислоты, кодирующие связывающие молекулы, и композиции, содержащие связывающие молекулы. Связывающие молекулы можно применять при диагностике, профилактике и/или лечении заболевания, вызванного вирусами гриппа В.
EA201491656A 2012-03-08 2013-03-07 Антитело, связывающееся с вирусами гриппа b и его применение EA028433B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608414P 2012-03-08 2012-03-08
EP12158525 2012-03-08
PCT/EP2013/054606 WO2013132007A1 (en) 2012-03-08 2013-03-07 Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Publications (2)

Publication Number Publication Date
EA201491656A1 true EA201491656A1 (ru) 2014-12-30
EA028433B1 EA028433B1 (ru) 2017-11-30

Family

ID=49115966

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491656A EA028433B1 (ru) 2012-03-08 2013-03-07 Антитело, связывающееся с вирусами гриппа b и его применение

Country Status (19)

Country Link
US (5) US8834881B2 (ru)
EP (1) EP2822968B1 (ru)
JP (1) JP6328061B2 (ru)
KR (1) KR102050615B1 (ru)
CN (2) CN108640989B (ru)
AR (1) AR091316A1 (ru)
AU (2) AU2013229488B2 (ru)
CA (1) CA2865594C (ru)
DK (1) DK2822968T3 (ru)
EA (1) EA028433B1 (ru)
ES (1) ES2664625T3 (ru)
HK (1) HK1200176A1 (ru)
MX (1) MX360056B (ru)
MY (1) MY170407A (ru)
NZ (1) NZ628382A (ru)
PH (2) PH12014501776A1 (ru)
SG (1) SG11201405226TA (ru)
TW (1) TWI628190B (ru)
WO (1) WO2013132007A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
WO2013086052A2 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
DK2822968T3 (en) 2012-03-08 2018-04-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN105209071A (zh) 2013-03-14 2015-12-30 抗非特公司 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
WO2014152946A2 (en) 2013-03-14 2014-09-25 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
CN113667013B (zh) 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
EP3076993A1 (en) * 2013-12-05 2016-10-12 Janssen Vaccines & Prevention B.V. Process for preparing influenza vaccines
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016010059A (es) * 2014-02-04 2017-04-27 Contrafect Corp Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
JP2017512471A (ja) * 2014-03-27 2017-05-25 ジェネンテック， インコーポレイテッド 抗ｂ型インフルエンザウイルス赤血球凝集素抗体及び使用方法
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
KR20170107562A (ko) 2015-02-05 2017-09-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 적혈구응집소에 대한 결합 분자 및 이의 용도
EP3294753A1 (en) * 2015-05-11 2018-03-21 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
WO2016200543A2 (en) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
CN107667114B (zh) 2015-06-01 2021-07-02 免疫医疗有限责任公司 中和抗流感结合分子及其用途
CN106243218B (zh) * 2015-06-03 2020-05-15 厦门大学 抗Flu B的广谱单克隆抗体及其用途
JP2017062300A (ja) * 2015-09-24 2017-03-30 セイコーエプソン株式会社 半導体装置、システム、電子機器、及び、音声認識方法
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法
WO2017148889A1 (en) 2016-03-01 2017-09-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza b neuraminidase
EP3496748A4 (en) 2016-08-05 2020-01-15 Medimmune, LLC ANTI-O2 ANTIBODIES AND USES THEREOF
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
SI3589730T1 (sl) 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
UY37620A (es) 2017-02-28 2018-08-31 Univ Pennsylvania Vacunas contra la gripe mediadas por aav novedosas
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JP7050807B2 (ja) 2017-04-13 2022-04-08 カディラ ヘルスケア リミティド 新規ペプチドベースのｐｃｓｋ９ワクチン
AU2019212480A1 (en) 2018-01-26 2020-09-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
CN112996910A (zh) * 2018-07-11 2021-06-18 动量制药公司 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
IL145849A0 (en) 1999-04-15 2002-07-25 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
EP1402025B1 (en) 2001-06-15 2006-02-01 Crucell Holland B.V. Chimaeric phages
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
EP1856271A4 (en) * 2005-03-08 2009-11-18 Medimmune Vaccines Inc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US8846867B2 (en) * 2007-06-26 2014-09-30 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
KR20110049802A (ko) * 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
EP2179811B1 (en) 2008-10-21 2018-10-03 Agie Charmilles SA Method and apparatus for controlling an electric discharge machining process
NO2842573T3 (ru) 2008-11-07 2018-02-24
JP5780762B2 (ja) * 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
JP5941841B2 (ja) * 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2814841A4 (en) * 2012-01-31 2015-06-17 Univ Osaka HUMAN MONOCLONAL ANTIBODIES FOR WIDE PROTECTION AGAINST INFLUENZA B VIRUS AND METHOD OF USE THEREOF
DK2822968T3 (en) 2012-03-08 2018-04-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
KR102050615B1 (ko) 2019-11-29
AR091316A1 (es) 2015-01-28
CA2865594A1 (en) 2013-09-12
JP2015518369A (ja) 2015-07-02
MX360056B (es) 2018-10-19
JP6328061B2 (ja) 2018-05-23
US20130243792A1 (en) 2013-09-19
ES2664625T3 (es) 2018-04-20
DK2822968T3 (en) 2018-04-16
US20140341929A1 (en) 2014-11-20
AU2013229488A1 (en) 2014-09-18
US8852595B2 (en) 2014-10-07
CN108640989B (zh) 2021-12-14
US9200064B2 (en) 2015-12-01
MY170407A (en) 2019-07-27
NZ729856A (en) 2021-12-24
US8834881B2 (en) 2014-09-16
EA028433B1 (ru) 2017-11-30
HK1200176A1 (en) 2015-07-31
NZ628382A (en) 2017-03-31
EP2822968A1 (en) 2015-01-14
US20160002318A1 (en) 2016-01-07
AU2018201647A1 (en) 2018-03-29
CA2865594C (en) 2021-07-27
TW201339173A (zh) 2013-10-01
PH12014501776B1 (en) 2014-11-10
US20140065165A1 (en) 2014-03-06
CN104169298A (zh) 2014-11-26
MX2014010755A (es) 2014-12-05
PH12014501776A1 (en) 2014-11-10
AU2018201647B2 (en) 2020-01-30
CN108640989A (zh) 2018-10-12
PH12015502553B1 (en) 2017-04-10
PH12015502553A1 (en) 2017-04-10
SG11201405226TA (en) 2014-11-27
TWI628190B (zh) 2018-07-01
US9005621B2 (en) 2015-04-14
WO2013132007A1 (en) 2013-09-12
KR20140135753A (ko) 2014-11-26
CN104169298B (zh) 2018-04-20
US20150037345A1 (en) 2015-02-05
AU2013229488B2 (en) 2017-12-07
EP2822968B1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201790134A3 (ru) Соединения имидазопирролидинонов
EA201171383A1 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2019007921A (es) Nuevos agentes de union a ha.
EA200970255A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX2014013678A (es) Agentes para neutralizacion de influenza.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
PH12015501360A1 (en) Bmp-6 antibodies
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа
EA201691749A1 (ru) Пептиды и способы применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM